For instance, studies propose that SLC12A5 may bolster bladder cancer progression through various signalling pathways, including nuclear factor kappa B, matrix metalloproteinase‐7, and SOX18.40 This evidence concerns the gene SOX18 and urinary bladder carcinoma.